Mrypofbxs3oahs9ooeof pharmi

Pharmidex Pharmaceutical Services

No Reviews Yet
No Completed Orders
London, GB

About Pharmidex Pharmaceutical Services

Founded: 2002

Founded in the UK in 2002, Pharmidex provides translational solutions in state-of-the-art facilities in London and Hatfield offering high-quality bespoke experimental data to support drug discovery and development.

We have comprehensive in-house laboratory facilities as well as extensive in vitro and in vivo... Show more »

Founded in the UK in 2002, Pharmidex provides translational solutions in state-of-the-art facilities in London and Hatfield offering high-quality bespoke experimental data to support drug discovery and development.

We have comprehensive in-house laboratory facilities as well as extensive in vitro and in vivo assay options.

This enables us to provide tailored studies designed to meet individual project needs. Through extensive knowledge of drug discovery and development, Pharmidex has been able to deliver a high level of customer satisfaction and forge several strategic international alliances, focusing on operations in the following areas:

  • In vitro ADMET
  • In vivo pharmacology
  • CNS drug discovery
  • Bioanalysis and metabolite Identification
  • Oncology and bioimaging
  • Cerense drug delivery
  • Toxicology
  • Pharmacokinetics
  • Physicochemical properties
Show less

Our Services (25)


ic

IND-Enabling Studies

Price on request
Request a quote for more information about this service.

ic

Bioanalysis

Price on request

Our bioanalysis service is focused on enabling our clients to make good decisions on progression of compounds towards candidate selection and beyond.

We believe the acquisition and timely delivery of high-quality bioanalytical data from in vitro and in vivo ADMET studies is critical to enable clients to identify the best... Show more »

Our bioanalysis service is focused on enabling our clients to make good decisions on progression of compounds towards candidate selection and beyond.

We believe the acquisition and timely delivery of high-quality bioanalytical data from in vitro and in vivo ADMET studies is critical to enable clients to identify the best candidates for progression into development.

To meet this demand we have established a team of scientists in modern laboratories in Hatfield with access to state-of-the-art equipment, including highly sensitive QTof and triple quadrupole mass spectrometry and UHPLC. The team has extensive experience in bioanalytical techniques and in the ADMET field as a whole, gained both from current positions at Pharmidex and previously at several of the world’s leading pharmaceutical R&D organisations.

Key services

  • Quantitative analysis of drugs, metabolites and biomarkers in complex biological matrices
  • Provision and interpretation of pharmacokinetic parameters
  • Cross-species metabolism comparisons
  • Structural characterisation of metabolites with identification of major metabolic vulnerabilities and potential sites of reactive metabolism.

Our philosophy is to work in a collaborative way with each client to develop a flexible, fit-for-purpose approach to suit their specific requirements. We are always happy to discuss study design and assist with data interpretation as necessary.

Show less

ic

CNS/Neurology Animal Models

Price on request

The World Health Organisation estimates that mental, neurological and substance use disorders account for 14% of the total global burden of disease.

Currently there are no disease-modifying therapies for the majority of neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease and multiple sclerosis. There... Show more »

The World Health Organisation estimates that mental, neurological and substance use disorders account for 14% of the total global burden of disease.

Currently there are no disease-modifying therapies for the majority of neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease and multiple sclerosis. There is an unmet clinical need to find therapeutic agents that offer a benefit beyond the symptomatic relief of the disease.

A limited understanding of the pathophysiology that underlies most psychiatric disorders means current medicaments for diseases such as schizophrenia, bipolar disorder or major depressive disorder only manage some aspects of the symptomatology and are only effective in a limited proportion of the patients.

Pharmidex is committed to supporting industry and academic partners in their search for developing safer and more efficacious CNS treatments. We offer our drug development expertise in CNS and provide a comprehensive research platform of techniques, including behaviour and neurochemistry analyses, in addition to bioanalysis.

Show less

ic

CYP Inhibition Assay

Price on request
  • Microsomes with recombinant baculovirus containing cDNA for individual human cytochrome P450 (CYP450) enzymes
  • Major CYP450 isozymes: 1A2, 2C9, 2C19, 2D6, 3A4
  • Single point (10μΜ) - % Inhibition
  • Dose response curves - IC50
  • Microsomes with recombinant baculovirus containing cDNA for individual human cytochrome P450 (CYP450) enzymes
  • Major CYP450 isozymes: 1A2, 2C9, 2C19, 2D6, 3A4
  • Single point (10μΜ) - % Inhibition
  • Dose response curves - IC50
Show less

ic

In vitro Metabolic Stability Assays

Price on request

Microsomal Metabolic Stability Assay

  • Containing metabolising enzymes for phase 1 (oxidation) metabolic processes
  • Two time points (0 and 60 min) at 37°C (% stability)
  • Various time points (typically 0, 15, 30, 60 and 120 min) at 37°C (half-life)
  • Intrinsic clearance (CLint) measurements

*Microsomal glucuronidation... Show more »

Microsomal Metabolic Stability Assay

  • Containing metabolising enzymes for phase 1 (oxidation) metabolic processes
  • Two time points (0 and 60 min) at 37°C (% stability)
  • Various time points (typically 0, 15, 30, 60 and 120 min) at 37°C (half-life)
  • Intrinsic clearance (CLint) measurements

Microsomal glucuronidation assay

  • Glutathione conjugation assay
  • Cross-species metabolic stability
  • Metabolite identification

Hepatocyte Metabolic Stability Assay

  • Containing metabolising enzymes for phase 1 (oxidation) and phase 2 (conjugation) metabolic processes
  • Two time points (0 and 60 min) at 37°C (% stability)
  • Various time points (typically 0, 15, 30, 60 and 120 min) at 37°C (half-life)
  • Intrinsic clearance (CLint) measurements
  • Predicted in vivo Hepatic Clearance (CLH)
  • Hepatic Extraction Ratio (E)
  • Cross-species metabolic stability
  • Metabolite identification

S9 Metabolic Stability Assay

  • Containing metabolising enzymes for phase 1 (oxidation) and phase 2 (conjugation) metabolic processes
  • Two time points (0 and 60 min) at 37°C (% stability)
  • Various time points (typically 0, 15, 30, 60 and 120 min) at 37°C (half-life)
  • Intrinsic clearance (CLint) measurements
  • Glucuronidation assay
  • Glutathione conjugation assay
  • Cross-species metabolic stability
  • Metabolite identification

Cytosol Metabolic Stability Assay

  • Containing metabolising enzymes for phase 1 (oxidation) and phase 2 (conjugation) metabolic processes
  • Two time points (0 and 60 min) at 37°C (% stability)
  • Various time points (typically 0, 15, 30, 60 and 120 min) at 37°C (half-life)
  • Intrinsic clearance (CLint) measurements
  • Cross-species metabolic stability
  • Metabolite identification

Plasma Stability Assay

  • Useful for interpreting discrepancies in plasma clinical samples and from in vivo pharmacokinetic studies
  • Two time points (0 and 60 min) at 37°C (% stability)
  • Various time points (typically 0, 15, 30, 60 and 120 min) at 37°C (half-life)
  • Cross-species plasma stability
  • Useful for interpreting discrepancies in clinical samples and from in vivo pharmacokinetic studies

Blood Stability Assay

  • Useful for interpreting discrepancies in blood clinical samples and from in vivo pharmacokinetic studies
  • Two time points (0 and 60 min) at 37°C (% stability)
  • Various time points (typically 0, 15, 30, 60 and 120 min) at 37°C (half-life)
  • Cross-species blood stability
  • Useful for interpreting discrepancies in clinical samples and from in vivo pharmacokinetic studies

Plasma Protein Binding Assay

  • Compounds may bind to plasma proteins so that only a small fraction of the drug is actually free in the plasma
  • Rapid equilibrium dialysis
  • Cross-species plasma protein binding
  • Results reported as % bound and fraction unbound (fu)

Blood Binding Assay

  • Compounds may bind to blood proteins so that only a small fraction of the drug is actually free in the blood
  • Rapid equilibrium dialysis
  • Cross-species blood binding
  • Results reported as % bound and fraction unbound (fu)

Cell Culture Media Binding Assay

  • Compounds may bind to serum proteins in cell culture media so that only a small fraction of the drug is actually free in the media
  • Rapid equilibrium dialysis
  • A diverse selection of media available
  • Results reported as % bound and fraction unbound (fu)

Brain Tissue Binding Assay

  • Compounds may bind to brain proteins and lipids so that only a small fraction of the drug is actually free in the plasma
  • Different to plasma protein binding as plasma has twice as much protein and brain has 20-fold more lipids
  • Rapid equilibrium dialysis method
  • Cross-species brain tissue binding
  • Results reported as % bound and fraction unbound (fu)

Tissue Binding Assay

  • Compounds may bind to tissue proteins and lipids so that only a small fraction of the drug is actually free in the plasma
  • Rapid equilibrium dialysis method
  • A wide range of tissues and organs available
  • Cross-species tissue binding
  • Results reported as % bound and fraction unbound (fu)

Brain Stability Assay

  • Certain molecules will be unstable in brain tissue; this is mainly due to enzymatic processes
  • Stability assay in 10% (or any other percentage) brain homogenate
  • Two time points (0 and 60 min) at 37°C (% stability)
  • Various time points (typically 0, 15, 30, 60 and 120 min) at 37°C (half-life)
  • Useful for interpreting discrepancies in clinical samples and from in vivo pharmacokinetic studies

Tissue Stability Assay

  • Certain molecules will be unstable in certain tissue; this is mainly due to enzymatic processes
  • Stability assay in tissue homogenate
  • A wide range of tissues and organs available
  • Two time points (0 and 60 min) at 37°C (% stability)
  • Various time points (typically 0, 15, 30, 60 and 120 min) at 37°C (half-life)
  • Useful for interpreting discrepancies in clinical samples and from in vivo pharmacokinetic studies

Urine Stability Assay

  • Certain molecules will be unstable in urine; this is mainly due to enzymatic processes
  • Acids, antioxidants or preservatives can be added to the urine samples. Prevents compound degradation in alkaline pH urine
  • Two time points (0 and 24 hours) at 37°C (% stability)
  • Various time points (typically 0, 1, 4, 8 and 24 hours) at 37°C (half-life)
  • Useful for interpreting discrepancies in clinical samples and from in vivo pharmacokinetic studies

Red Blood Cell Partitioning Assay

  • Some drugs have a significantly higher affinity for red blood cells than for plasma
  • Useful for interpreting discrepancies in clinical samples and from in vivo pharmacokinetic studies
  • Calculation of RBC/plasma ratio (KRBC/PL)
  • Useful for interpreting discrepancies in clinical samples and from in vivo pharmacokinetic studies
  • Gastric Juice Stability Assay
  • For orally administered drugs, the stability in gastric fluid is an important consideration
  • Using an artificial gastric fluid recipe
  • Two time points (0 and 60 min) at 37°C (% stability)
  • Various time points (typically 0, 15, 30, 60 and 120 min) at 37°C (half-life)
  • Intestinal Juice Stability Assay
  • For orally administered drugs, the stability in intestinal fluid is an important consideration
  • Using an artificial intestinal fluid recipe
  • Two time points (0 and 60 min) at 37°C (% stability)
  • Various time points (typically 0, 15, 30, 60 and 120 min) at 37°C (half-life)
Show less

ic

Drug Transporter Assays

Price on request

MDR1-MDCK Permeability Assay

  • Mono or bi-directional transport
  • Apical-to-basolateral permeability
  • Basolateral to apical permeability
  • Papp values
  • Transporter inhibition assays

Caco-2 Permeability Assay

  • Mono or bi-directional transport
  • Apical-to-basolateral permeability
  • Basolateral to apical permeability
  • Papp values
  • Transporter inhibition assays

MDR1-MDCK Permeability Assay

  • Mono or bi-directional transport
  • Apical-to-basolateral permeability
  • Basolateral to apical permeability
  • Papp values
  • Transporter inhibition assays

Caco-2 Permeability Assay

  • Mono or bi-directional transport
  • Apical-to-basolateral permeability
  • Basolateral to apical permeability
  • Papp values
  • Transporter inhibition assays
Show less

ic

Solubility and Dissolution Testing

Price on request
Request a quote for more information about this service.

ic

LogP/LogD Determination

Price on request

Partition Coefficient (Log D) Assay

  • Log D coefficient is the ratio of concentrations of a compound in the two phases of a mixture of two immiscible solvents at equilibrium
  • This method involves dissolving the compound in a known volume of octanol (hydrophobic) and water or PBS (hydrophilic)
  • Shake-flask method

Partition Coefficient (Log D) Assay

  • Log D coefficient is the ratio of concentrations of a compound in the two phases of a mixture of two immiscible solvents at equilibrium
  • This method involves dissolving the compound in a known volume of octanol (hydrophobic) and water or PBS (hydrophilic)
  • Shake-flask method
Show less

ic

Receptor Binding Assays

Price on request
  • We can investigate test compounds at various receptor types and subtypes
  • To elucidate both receptor density (Bmax) and compound potency (affinity) (IC50/Ki)
  • Performed in cloned cell lines, expressing individual receptors or native tissue
  • We can investigate test compounds at various receptor types and subtypes
  • To elucidate both receptor density (Bmax) and compound potency (affinity) (IC50/Ki)
  • Performed in cloned cell lines, expressing individual receptors or native tissue
Show less

ic

Protein Aggregation Analysis

Price on request
  • In vitro protein aggregation assays provide a simple homogenous test system for monitoring peptide and protein aggregation in solution
  • The assay is based on the property of dye in which fluorescence is increased when bound to aggregated proteins/peptides
  • These assays are useful for defining optimal storage formulations for... Show more »
  • In vitro protein aggregation assays provide a simple homogenous test system for monitoring peptide and protein aggregation in solution
  • The assay is based on the property of dye in which fluorescence is increased when bound to aggregated proteins/peptides
  • These assays are useful for defining optimal storage formulations for proteins and for screening of compounds that promote or inhibit protein aggregation
  • Compounds that inhibit build-up of amyloid-β (Aβ) protein deposits in Alzheimer's disease (AD) brain are potential therapeutic agents
  • Basic aggregation assays consist of a fluorescence dye and a protein of interest
Show less

ic

Free Radical Analysis

Price on request
  • Free radical accumulation in the body generates oxidative stress and cell damage
  • Assessment of the compound to induce lipid peroxidation
  • Assessment of the compound to inhibit known lipid peroxidation-causing agents
  • Performed in any tissue of choice
  • Free radical accumulation in the body generates oxidative stress and cell damage
  • Assessment of the compound to induce lipid peroxidation
  • Assessment of the compound to inhibit known lipid peroxidation-causing agents
  • Performed in any tissue of choice
Show less

ic

In vitro Hemolysis Assay

Price on request
  • Red blood cells are tested at decreasing strengths of hypotonic saline solution
  • Data represented as the NaCl concentration (g/L) that gives 50% lysis
  • Median Corpuscular Fragility (MCF)
  • Red blood cells are tested at decreasing strengths of hypotonic saline solution
  • Data represented as the NaCl concentration (g/L) that gives 50% lysis
  • Median Corpuscular Fragility (MCF)
Show less

ic

Biomarker Analysis

Price on request
  • Bespoke or established assays for biomarkers
  • Enzyme, hormone, peptide, receptor or other biomarkers
  • Useful for end-point analysis in clinical and non-clinical studies
  • Bespoke or established assays for biomarkers
  • Enzyme, hormone, peptide, receptor or other biomarkers
  • Useful for end-point analysis in clinical and non-clinical studies
Show less

ic

In vitro ADME/DMPK Studies

Price on request

To address the challenges encountered within drug discovery and development Pharmidex offers an extensive suite of absorption, distribution, metabolism, excretion and toxicity/pharmacokinetic (ADMET) in vitro assay solutions.

To address the challenges encountered within drug discovery and development Pharmidex offers an extensive suite of absorption, distribution, metabolism, excretion and toxicity/pharmacokinetic (ADMET) in vitro assay solutions.

Show less

ic

Metabolic Disease Animal Models

Price on request

Pharmidex offers a range of in vivo validated assays to assess the therapeutic potential of anti-obesity and anti-diabetic agents.

Genetic and diet-induced rodent models are used to determine the efficacy of candidate therapeutics and inform mechanism of action. Studies are managed by experts with high records of success in... Show more »

Pharmidex offers a range of in vivo validated assays to assess the therapeutic potential of anti-obesity and anti-diabetic agents.

Genetic and diet-induced rodent models are used to determine the efficacy of candidate therapeutics and inform mechanism of action. Studies are managed by experts with high records of success in world-leading pharmaceutical companies.

For anti-obesity agents, measurements include energy expenditure, metabolic rate, body composition and food intake, such as impact of pair feeding.

For anti-diabetic agents, glucose tolerance, insulin sensitivity and/or insulin tolerance assessments are coupled with a range of plasma biomarkers to evaluate efficacy and mechanism of action.

Various administration routes are available and studies may be coupled with pharmacokinetic measurements to inform on PK/PD, providing a robust pre-clinical package for pre-development assessment and project decisions.

Data analysis and study reports are of the highest standard, and may be included in Investigational New Drug (IND) applications.

Show less

ic

Drug Absorption Studies

Price on request
Request a quote for more information about this service.

ic

Metabolite Identification

Price on request
Request a quote for more information about this service.

ic

In vivo PK/PD Studies

Price on request
Request a quote for more information about this service.

ic

Physicochemical Testing

Price on request

An understanding of simple physicochemical properties can help drive the lead optimisation and lead identification phases of drug discovery.

Many pharmacologically active molecules fail to progress as a result of suboptimal properties, which are sometimes related to inappropriate physicochemical characteristics.

At Pharmidex we... Show more »

An understanding of simple physicochemical properties can help drive the lead optimisation and lead identification phases of drug discovery.

Many pharmacologically active molecules fail to progress as a result of suboptimal properties, which are sometimes related to inappropriate physicochemical characteristics.

At Pharmidex we can conduct the following analyses to determine whether your compound of interest has the optimal physicochemical properties for progression into development:

  • pH solubility/stability
  • Partition Coefficient (Log D) Assay
  • Thermodynamic Solubility
Show less

ic

Toxicology

Price on request

Our MHRA- and OLAW-accredited toxicology department will help you with your preclinical and other early-stage product development needs to assure product safety and regulatory compliance.

Our knowledgeable and experienced scientists will design and implement standard and customised bespoke discovery toxicology or regulatory... Show more »

Our MHRA- and OLAW-accredited toxicology department will help you with your preclinical and other early-stage product development needs to assure product safety and regulatory compliance.

Our knowledgeable and experienced scientists will design and implement standard and customised bespoke discovery toxicology or regulatory toxicology studies in a timely and professional manner, helping you to progress to Investigational New Drug (IND) and New Drug Application (NDA) submissions.

Depending on your requirements, various administration routes can be utilised, such as oral, intravenous, subcutaneous, topical and intraperitoneal. Pharmidex has state-of-the art facilities to perform not only toxicity studies, but any surgical preparation, such as multiple cannulation for serial sampling during toxicokinetic studies. This can be useful for critical evaluation of drug disposition at toxicologic doses and also to establish the relationships between toxicokinetic values and the occurrence and time course of toxic events to save your time and resources.

Your toxicity study will be performed according to the agreed Protocol, Testing Facility Standard Operating Procedures, OLAW guidelines and British Home Office regulations. If requested, your study can be compliant with the Good Laboratory Practice Regulations 1999 (S.I. No. 3106), as amended by the 2004 regulations (S.I. No. 994), which are based on the principles of good laboratory practice as adopted by the Organisation for Economic Co-operation and Development (OECD), ENV/MC/CHEM (98) 17.

OECD guidelines that will be used for your study designs may include the following:

  • OECD 402 – Acute Dermal Toxicity
  • OECD 407 – Repeated Dose 28-Day Oral Toxicity Study in Rodents
  • OECD 408 – Repeated Dose 90-Day Oral Toxicity Study in Rodents
  • OECD 410 – Repeated Dose Dermal Toxicity: 21/28-day Study
  • OECD 411 – Subchronic Dermal Toxicity: 90-day Study
  • OECD 420 – Acute Oral Toxicity – Fixed Dose Procedure
  • OECD 423 – Acute Oral Toxicity – Acute Toxic Class Method
  • OECD 425 – Acute Oral Toxicity: Up-and-Down Procedure
  • OECD 451 – Carcinogenicity Studies
  • OECD 452 – Chronic Toxicity Studies
  • OECD 453 – Combined Chronic Toxicity/Carcinogenicity Studies

Your studies will be quickly initiated and you can count on report preparation that will meet your milestones or deadlines. Customer satisfaction, high quality and flexibility are core values of Pharmidex’s corporate philosophy, which will help to fast-forward your drug discovery programmes, assist in candidate selection and to support the first-in-human studies.

Show less

ic

Repeat-Dose Toxicity Studies

Price on request
Request a quote for more information about this service.

ic

Dermal Toxicity Studies

Price on request
Request a quote for more information about this service.

ic

Carcinogenicity/Tumorigenicity Testing

Price on request
Request a quote for more information about this service.

ic

Respiratory Disease Animal Models

Price on request

Respiratory diseases are increasing in prevalence around the globe and affect millions of people annually.

Current World Health Organisation estimates indicate that currently 235 million people worldwide suffer with asthma, 64 million with chronic obstructive pulmonary disease (COPD) and millions with allergic rhinitis. These... Show more »

Respiratory diseases are increasing in prevalence around the globe and affect millions of people annually.

Current World Health Organisation estimates indicate that currently 235 million people worldwide suffer with asthma, 64 million with chronic obstructive pulmonary disease (COPD) and millions with allergic rhinitis. These diseases put a huge burden on individuals and society as the unmet medical need is substantial, with patients often remaining symptomatic for many years despite using the best available therapies.

Pharmidex is committed to supporting industry and academic partners in their search for developing safer and more efficacious treatment for Respiratory disease. We offer our drug development expertise in Respiratory therapeutics and provide a comprehensive research service, including pharmacodynamic assays and translatable respiratory disease models, in addition to bioanalysis.

Show less

ic

Animal in vivo Imaging

Price on request

Bioimaging is a non-invasive process that allows in vivo imaging of biological changes in the body in response to drug treatment in progressively greater depth and detail, including receptor kinetics, molecular and cellular signaling and interactions, and the movement of molecules through membranes.

Being mostly non-invasive,... Show more »

Bioimaging is a non-invasive process that allows in vivo imaging of biological changes in the body in response to drug treatment in progressively greater depth and detail, including receptor kinetics, molecular and cellular signaling and interactions, and the movement of molecules through membranes.

Being mostly non-invasive, bioimaging offers precise tracking of metabolites that can be used as biomarkers for disease identification, progress and treatment response. Bioimaging is thus a powerful tool for viewing the internal workings of the body and its diseases.

At Pharmidex we offer two systems for non-invasive in vivo imaging for both small rodents using the In-Vivo FX PRO and larger animals (pigs and sheep) using our other system.

Key benefits

  • Elevates sensitivity, throughput and ease of use to an entirely new level
  • Combines high-sensitivity optical molecular imaging, radioisotopic imaging, and high-resolution digital x-ray to deliver precise anatomical localization of molecular and cellular biomarkers in vivo
  • New full precision automation simplifies complex multimodal imaging protocols for small animal imaging
  • Protects your investment with a seamless upgrade path to multispectral imaging capabilities
Show less

Not finding what you're looking for?

Get info on this provider's capabilities without requesting a quote.
Missing Avatar

Ash Alavijeh

Operations manager

Pharmidex Pharmaceutical Services has not received any reviews.

Pharmidex Pharmaceutical Services has not received any endorsements.